Clinical Rheumatology

, Volume 15, Issue 5, pp 450–456 | Cite as

The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis

  • J. H. L. M. van Groenendael
  • H. M. Markusse
  • B. A. C. Dijkmans
  • F. C. Breedveld
Originals

Summary

The efficacy of ranitidine in the treatment of NSAID-related dyspeptic symptoms with and without peptic ulcer disease (PUD) was investigated in 124 patients with rheumatoid arthritis (RA) and osteoarthritis (OA). The patients, who continued the use of NSAIDs were investigated by gastroduodenoscopy. Patients with PUD received open label ranitidine 150 mg b.i.d. and the patients without PUD were randomly allocated to receive ranitidine 150 mg b.i.d. or placebo for 4 weeks. PUD was found in 36 (26%) consecutive patients who presented with dyspeptic symptoms. Of these patients dyspeptic symptoms had disappeared in 8 (26%) of 31 evaluable patients and PUD was healed in 18 (56%) patients after 4 weeks of treatment. After 8 weeks of treatment PUD was healed in 27 (87%) patients. Of the remaining patients without PUD dyspeptic symptoms had disappeared in 24 (26%) of the ranitidine-treated patients which was significantly better (p<0.02) than the 5 (6%) placebo-treated patients. The minor mucosal lesions found in this patient group improved to a similar extent in the ranitidine and placebo-treated patients although 1 placebo-treated patient deteriorated and 2 placebo-treated patients developed PUD during the 4 weeks of study. The results of this study show that oral ranitidine 150 mg b.i.d. is effective in the treatment of both dyspeptic symptoms and mucosal lesions in RA and OA patient who continue the use of NSAIDs.

Key words

Ranitidine NSAID's Rheumatoid Arthritis Osteoarthritis Dyspeptic Symptoms 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Haslock, I. Prevalence of NSAID-induced gastrointestinal morbidity and mortality. J Rheumatol 1990, 17 (suppl 20); 2–6.Google Scholar
  2. 2.
    Blechman, W.J., Schmid, F.R., April, P.A. et al. Ibuprofen or aspirin in rheumatoid arthritis therapy. JAMA 1975, 233, 336–340.PubMedGoogle Scholar
  3. 3.
    Ehrlich, G.E., Miller, S.B., Zeiders, R.S. Choline magnesium trisalicylate versus ibuprofen in rheumatoid arthritis. Rheumatol Rehab 1980, 19, 30–41.Google Scholar
  4. 4.
    O'Brien, W.M. Ulcerogenic properties of anti-inflammatory drugs. Pharmacology 1982, 25 (suppl 3), 9–11.PubMedGoogle Scholar
  5. 5.
    Mc Millen, J.I. Tolmetin sodium vs ibuprofen in rheumatoid arthritic patients previously untreated with either drug: a double-blind crossover study. Curr Ther Res 1977, 22, 266–275.Google Scholar
  6. 6.
    Bower, R.J., Umbenbauer, E.R., Hercus, V. Clinical evaluation of sulindac: A new nonsteroidal anti-inflammatory drug. Advances in Inflammation Research, Vol 1. New York: RAven Press, 1979, 559–567.Google Scholar
  7. 7.
    Coles, L.S., Fries, J.F., Kraines, R.G., Roth, S.H. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983, 74, 820–828PubMedGoogle Scholar
  8. 8.
    Janssen, M., Dijkmans, B.A.C., van der Sluys, F.A. et al. Upper gastrointestinal complaints in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol 1992, 31, 747–752.PubMedGoogle Scholar
  9. 9.
    Langman, M.J.S., Brooks, P., Hawkey, C.J. Silverstein, F., Yeomans, N. Nonsteroidal anti-inflammatory drug associated ulcer: epidemiology causation and treatment. J Gastroenterol Hepatol 1991, 6, 442–449.PubMedGoogle Scholar
  10. 10.
    Gabriel, S.E., Jaakkimainen, L., Bombardieri, C. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drug. A meta-analysis. Ann Int Med 1991, 115, 787–96.PubMedGoogle Scholar
  11. 11.
    Armstrong, C.P., Blowe, A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987, 28, 527–532.PubMedGoogle Scholar
  12. 12.
    Janssen, M., Dijkmans, B.A.C., Lames, C.B.H.W., et al. A gastroscopic study of the predictive value of risk factors for nonsteroidal anti-inflammatory drug associated ulcer disease in rheumatoid arthritis patients. Br J Rheumatol 1994, 33, 449–454.PubMedGoogle Scholar
  13. 13.
    Ehsanullah, R.S.B., Page, M.C., Tildesley, G., Wood, J.R. Prevention of gastriduodenal damage induced by nonsteroidal anti-inflammatory drugs: a controlled trial of ranitidine. Br Med J 1988, 297, 1017–1021.Google Scholar
  14. 14.
    Deventer van, G.M., Elashoff, J.D., Reedy, T.J., Schneidman, D., Walsh, J.H. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. New Engl J Med 1989, 320, 1113–1119.PubMedGoogle Scholar
  15. 15.
    Jensen, D.M., Cheng, S., Kovacs, K.O.G., Randall, G. et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. New Engl J Med 1994, 330, 382–386.PubMedGoogle Scholar
  16. 16.
    Penston, J.G. A decade of experience with long-term continuous treatment of peptic ulcers with H2-receptor antagonists. Aliment Pharmacol Therapeut 1993, 7, 27–33.Google Scholar
  17. 17.
    Murray, W.R., Cooper, G., Laferla, G., Rogers, P., Archibald, M. Maintenance ranitidine treatment after hemorrhage from a duodenal ulcer: a 3-year study. Scan J Gastroenterol 1988, 23, 183–187.Google Scholar
  18. 18.
    Wolde ten, S., Dijkmans, B.A.C., Janssen, M., Hermans, J., Lamers, C.H.B.W. A double blind placebo-controlled study of ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs. Arthritis Rheum 1994, 9 (suppl), S258.Google Scholar
  19. 19.
    Hotz, J., Kark, W. Efficacy of ranitidine in non-ulcer dyspepsia; fact of fancy? (abstract) Gastroenterol 1991, 100 (part 2), A85.Google Scholar
  20. 20.
    Saundes, J.H.B., Oliver, R.J., Higson, D.L., Dyspepsia: incidence of non-ulcer disease in a controlled trial in general population. Br Med J 1986, 292, 665–668.Google Scholar
  21. 21.
    Arnett, F.C., Edworthy, S.M. Cloch, D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheum 1988, 31, 315–324.Google Scholar
  22. 22.
    Altman, R., Alarcon, G., Appelrouth, D. et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arhtritis Rheum 1990, 33, 1601–1610.Google Scholar
  23. 23.
    Altman, R., Alarcon, G., Appelrouth, D. et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991, 34, 505–514.PubMedGoogle Scholar
  24. 24.
    Altman, R., Asch, E., Bloch, G. et al. Development for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986, 29, 1039–1049.PubMedGoogle Scholar
  25. 25.
    Lanza, F.L., Royer, G.L., Nelson, R.S., Chen, T.T., Seckman, C.E., Raack, M.F. A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol 1981, 75, 17–21.PubMedGoogle Scholar
  26. 26.
    Huson, N., Hawkey, C.J. Non-steroidal anti-inflammatory drug associated upper gastrointestinal ulceration and complications. Europ J Gastroenterol Hepatol 1993, 5L, 412–419.Google Scholar
  27. 27.
    Fries, J.F., Mille, S.R., Spitz, P.W., Williams, C.A., Hubert, H.B., Bloch, D.A. Identification of patients at risk for gastropathy associated with NSAID use. J Rheumatol 1990, 17 (Suppl 20), 12–19.Google Scholar
  28. 28.
    Shaikh, S., Mills, J.G., Darekar, B., Wood, J.R. Ranitidine (150 mg bd) is effective inj preventing peptic ulceration in arthritic patients receiving diclofenac (150 mg/day). Gut 1993, 34 (suppl. 1), S14.Google Scholar
  29. 29.
    Bianchi Porro, G., Lazzaroni, B. Prevention and treatment of nonsteroidal gastroduodenal lesions. Eur J Gastroenterol Hepatol 1993, 5, 420–432.Google Scholar
  30. 30.
    Ehsanullag, R.S.B., Page, M.C., Tildesley, G., Wood, J.R. A place-bo controlled trial study of ranitidine in healing NSAID associated gastric and duodenal ulcers. Br J Rheumatol 1990, 2 (suppl. 2), 9.Google Scholar
  31. 31.
    Lanza, F.L., Aspinall, R.L., Swabb, E.A., Davis, R.E., Rack, M.F. Rubin A. Double-blind-, placebo-controlled endoscopic comparison of the mucosal protective effects of misoprostol versus cimetidine on tolmetin-induced mucosal injury to the stomach and duodenum. Gastroentorology 1988, 95, 289–294.Google Scholar
  32. 32.
    Valentini, M., Cannizzaro, R., Bortolussi, R., Sozzi, M., Fracasso A., Fornasarig, M. Misoprostol versus ranitidine in prevention of gastroduodenal mucosal injury in cancer patients. Br J Rheumatology 1992, 31, 181.Google Scholar

Copyright information

© Clinical Rheumatology 1996

Authors and Affiliations

  • J. H. L. M. van Groenendael
    • 1
  • H. M. Markusse
    • 1
  • B. A. C. Dijkmans
    • 1
  • F. C. Breedveld
    • 1
  1. 1.Department of RheumatologyUniversity HospitalLeidenThe Netherlands

Personalised recommendations